153 related articles for article (PubMed ID: 36451334)
1. SOURCE beyond first-line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first-line palliative systemic therapy.
Kuijper SC; Pape M; Haj Mohammad N; van Voorthuizen T; Verhoeven RHA; van Laarhoven HWM
Int J Cancer; 2023 Mar; 152(6):1202-1209. PubMed ID: 36451334
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.
Dijksterhuis WPM; Verhoeven RHA; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Int J Cancer; 2020 Apr; 146(7):1889-1901. PubMed ID: 31340065
[TBL] [Abstract][Full Text] [Related]
3. SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer.
van den Boorn HG; Abu-Hanna A; Haj Mohammad N; Hulshof MCCM; Gisbertz SS; Klarenbeek BR; Slingerland M; Beerepoot LV; Rozema T; Sprangers MAG; Verhoeven RHA; van Oijen MGH; Zwinderman KH; van Laarhoven HWM
J Natl Compr Canc Netw; 2021 Apr; 19(4):403-410. PubMed ID: 33636694
[TBL] [Abstract][Full Text] [Related]
4. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
[TBL] [Abstract][Full Text] [Related]
5. Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
Dijksterhuis WPM; Verhoeven RHA; Pape M; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; Lemmens VEPP; van Oijen MGH; van Laarhoven HWM
Eur J Cancer; 2020 Nov; 139():107-118. PubMed ID: 32980749
[TBL] [Abstract][Full Text] [Related]
6. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
7. SOURCE-PANC: A Prediction Model for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Based on Nationwide Population-Based Data.
van den Boorn HG; Dijksterhuis WPM; van der Geest LGM; de Vos-Geelen J; Besselink MG; Wilmink JW; van Oijen MGH; van Laarhoven HWM
J Natl Compr Canc Netw; 2021 Jul; 19(9):1045-1053. PubMed ID: 34293719
[TBL] [Abstract][Full Text] [Related]
8. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.
Kim SY; Yoon MJ; Park YI; Kim MJ; Nam BH; Park SR
Gastric Cancer; 2018 May; 21(3):453-463. PubMed ID: 28828688
[TBL] [Abstract][Full Text] [Related]
9. SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer.
van den Boorn HG; Abu-Hanna A; Ter Veer E; van Kleef JJ; Lordick F; Stahl M; Ajani JA; Guimbaud R; Park SH; Dutton SJ; Bang YJ; Boku N; Mohammad NH; Sprangers MAG; Verhoeven RHA; Zwinderman AH; van Oijen MGH; van Laarhoven HWM
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30764578
[TBL] [Abstract][Full Text] [Related]
10. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
11. Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy.
Ma T; Wu ZJ; Xu H; Wu CH; Xu J; Peng WR; Fan LL; Sun GP
BMC Cancer; 2019 Aug; 19(1):852. PubMed ID: 31462229
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the value of 7th editions of UICC-AJCC esophageal and gastric cancer TNM staging systems for prognostic prediction of adenocarcinoma of esophagogastric junction (Siewert type II)].
Shi GD; Luo ZL; Fu MY; Tian D; Zhang L; Zhang KP
Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):916-21. PubMed ID: 25623766
[TBL] [Abstract][Full Text] [Related]
13. A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers.
Sclafani F; Smyth E; Cunningham D; Chau I; Turner A; Watkins D
Clin Colorectal Cancer; 2014 Jun; 13(2):94-9. PubMed ID: 24332356
[TBL] [Abstract][Full Text] [Related]
14. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab.
Custodio A; Carmona-Bayonas A; Jiménez-Fonseca P; Sánchez ML; Viudez A; Hernández R; Cano JM; Echavarria I; Pericay C; Mangas M; Visa L; Buxo E; García T; Rodríguez Palomo A; Álvarez Manceñido F; Lacalle A; Macias I; Azkarate A; Ramchandani A; Fernández Montes A; López C; Longo F; Sánchez Bayona R; Limón ML; Díaz-Serrano A; Hurtado A; Madero R; Gómez C; Gallego J
Br J Cancer; 2017 Jun; 116(12):1526-1535. PubMed ID: 28463962
[TBL] [Abstract][Full Text] [Related]
15. Survival nomogram for patients with metastatic siewert type II adenocarcinoma of the esophagogastric junction: a population-based study.
Chen K; Deng X; Yang Z; Yu D; Zhang X; Zhang J; Xie D; He Z; Cheng D
Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):757-764. PubMed ID: 32552040
[TBL] [Abstract][Full Text] [Related]
16. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
17. [Effect of number of metastatic lymph nodes and metastatic lymph node ratio on the prognosis in patients with adenocarcinoma of the esophagogastric junction after curative resection].
Zhang H; Chen C; Yue J; Ma M; Ma Z; Yu Z
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):141-6. PubMed ID: 24796465
[TBL] [Abstract][Full Text] [Related]
18. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
19. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
20. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
